Abstract:Cancer cell metabolism is quite different from normal cells. Targeting cancer metabolism and untuning the tumor metabolic machine has emerged as a promising strategy for cancer therapy. We have developed a multi-functional Re-dca conjugate (Re-dca 2) by conjugating the metabolic modulator dichloroacetate (DCA) to mitochondria-targeted rhenium(I) complex, allowing its efficient penetration into cancer cells and selective accumulation in mitochondria, thus achieving the cancer cell metabolism reversal from glycolysis to glucose oxidation at pharmacologically relevant DCA doses. Mechanism studies confirm the inhibition effect of Re-dca 2 on the activity of pyruvate dehydrogenase kinase (PDK) and capture the metabolic reversal window in Re-dca 2 treated NCI-1229 cells at the early stage of drug treatment, resulting in selective killing of malignant cells cocultured with normal cells, significant inhibition of cancer cell metastasis and invasion, as well as excellent anti-angiogenesis activities in zebrafish embryos. By comparison, DCA-free Re(I) analogue is also investigated under the same conditions. Although this analogue also exhibits cytotoxicity due to the Re(I) core, metabolic reversal is not induced by this analogue and its anti-metastasis activity is much lower than Re-dca 2, indicating the synergistic effect of Re(I) core and DCA moiety on cancer therapy. In vivo anti-cancer investigations also indicate that the mitochondria-targeted Re-dca 2 can effectively inhibit the tumor growth without affecting the body weight of nude mice, and the therapeutic effect is much better than the DCA-free Re(I) analogue 2a. Simultaneously, the O2-sensitive phosphorescent lifetimes of Re-dca 2 can be utilized for PLIM imaging of intracellular oxygen consumption, thus reflecting the Re-dca 2 induced glycolysis-to-glucose oxidation reversal at the early drug treatment stage. The excellent phosphorescence of Re-dca 2 can also be utilized for real-time tracking of mitochondrial morphological changes during treatment. In a word, rational design of phosphorescent metallodrug and metabolic modulator conjugates for synergistic treatment is a promising strategy for simultaneous untuning and tracking tumor metabolic machine, thus providing new clues for cancer therapy and mechanisms.

Targeting Energy Metabolism by a Platinum(IV) Prodrug As an Alternative Pathway for Cancer Suppression.

Restraining Cancer Cells by Dual Metabolic Inhibition with a Mitochondrion‐Targeted Platinum(II) Complex

Regulating Tumor Glycometabolism and Immune Microenvironment by Inhibiting Lactate Dehydrogenase with Platinum(IV) Complexes

Regulating Tumor Glycometabolism and the Immune Microenvironment by Inhibiting Lactate Dehydrogenase with Platinum(iv) Complexes

Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate

Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes.

Cancer Cell-Targeted Cisplatin Prodrug Delivery in Vivo Via Metabolic Labeling and Bioorthogonal Click Reaction

Dual Mitochondria- and DNA-Targeting Coumarin-Pt(IV) Prodrug for the Enhancement of Anticancer Performance

Mitochondria-targeted platinum(ii) complexes: dual inhibitory activities on tumor cell proliferation and migration/invasion via intracellular trafficking of β-catenin.

Dendronized-Polymer Disturbing Cells' Stress Protection by Targeting Metabolism Leads to Tumor Vulnerability.

An advanced multifunctional prodrug combining photodynamic therapy with chemotherapy for highly efficient and precise tumor ablation

Reprogramming Energy Metabolism with Synthesized PDK Inhibitors Based on Dichloroacetate Derivatives and Targeted Delivery Systems for Enhanced Cancer Therapy

Cancer Cell Membrane Biomimetic Composites of Cisplatin Prodrug for Targeted Eradication of Circulating Tumor Cells in Whole Blood

A Dual Action Platinum(IV) Complex with Self‐assembly Property Inhibits Prostate Cancer through Mitochondrial Stress Pathway

Targeting Tumor Metabolism for Cancer Treatment: is Pyruvate Dehydrogenase Kinases (pdks) a Viable Anticancer Target?

Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective PlatinumIV Prodrug Against Triple Negative Breast Cancer.

Multifunctional Platinum(iv) Complex Bearing HDAC Inhibitor and Biotin Moiety Exhibits Prominent Cytotoxicity and Tumor-Targeting Ability

A Biodegradable Nanodrug with Highly Efficient Treatment Effect by Remodeling Tumor Microenvironment and Manipulating Energy Metabolism Against Colorectal Cancer

Targeted Reversal and Phosphorescence Lifetime Imaging of Cancer Cell Metabolism Via a Theranostic Rhenium(i)-Dca Conjugate.

A Platinum-Ruthenium Hybrid Prodrug with Multi-Enzymatic Activities for Chemo-Catalytic Therapy of Hypoxic Tumors

Dual Inhibition of Oxidative Phosphorylation and Glycolysis to Enhance Cancer Therapy